FATE Stock Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fate Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.90 |
| 52 Week High | US$8.83 |
| 52 Week Low | US$1.63 |
| Beta | 1.68 |
| 1 Month Change | -42.31% |
| 3 Month Change | -38.00% |
| 1 Year Change | -25.86% |
| 3 Year Change | -94.55% |
| 5 Year Change | -80.05% |
| Change since IPO | -41.09% |
Recent News & Updates
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23
Recent updates
Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01Fate Therapeutics: Data Playing Catchup With Valuation
Dec 06Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans
Oct 16Shareholder Returns
| FATE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | 0.5% | 2.7% |
| 1Y | -25.9% | 3.4% | 26.0% |
Return vs Industry: FATE underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: FATE underperformed the US Market which returned 25% over the past year.
Price Volatility
| FATE volatility | |
|---|---|
| FATE Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FATE's share price has been volatile over the past 3 months.
Volatility Over Time: FATE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 181 | J. Wolchko | www.fatetherapeutics.com |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
Fate Therapeutics, Inc. Fundamentals Summary
| FATE fundamental statistics | |
|---|---|
| Market cap | US$421.12m |
| Earnings (TTM) | -US$160.93m |
| Revenue (TTM) | US$63.53m |
7.0x
P/S Ratio-2.8x
P/E RatioIs FATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FATE income statement (TTM) | |
|---|---|
| Revenue | US$63.53m |
| Cost of Revenue | US$161.70m |
| Gross Profit | -US$98.16m |
| Other Expenses | US$62.77m |
| Earnings | -US$160.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | -154.51% |
| Net Profit Margin | -253.30% |
| Debt/Equity Ratio | 0% |
How did FATE perform over the long term?
See historical performance and comparison